Oak Ridge Investments LLC Has $8.88 Million Stake in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Oak Ridge Investments LLC grew its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 69.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 17,021 shares of the medical equipment provider's stock after buying an additional 6,961 shares during the quarter. Oak Ridge Investments LLC's holdings in Intuitive Surgical were worth $8,884,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Mirador Capital Partners LP raised its holdings in Intuitive Surgical by 1.4% during the third quarter. Mirador Capital Partners LP now owns 3,526 shares of the medical equipment provider's stock worth $1,732,000 after purchasing an additional 50 shares in the last quarter. Exome Asset Management LLC raised its stake in shares of Intuitive Surgical by 16.8% in the 3rd quarter. Exome Asset Management LLC now owns 7,427 shares of the medical equipment provider's stock worth $3,649,000 after buying an additional 1,069 shares in the last quarter. Consolidated Planning Corp lifted its holdings in shares of Intuitive Surgical by 17.4% in the third quarter. Consolidated Planning Corp now owns 8,099 shares of the medical equipment provider's stock valued at $3,979,000 after buying an additional 1,198 shares during the period. Wealth Enhancement Advisory Services LLC boosted its stake in Intuitive Surgical by 73.2% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 270,029 shares of the medical equipment provider's stock valued at $132,657,000 after buying an additional 114,149 shares in the last quarter. Finally, Czech National Bank grew its holdings in Intuitive Surgical by 6.9% during the fourth quarter. Czech National Bank now owns 77,227 shares of the medical equipment provider's stock worth $40,309,000 after acquiring an additional 4,970 shares during the period. 83.64% of the stock is currently owned by institutional investors.

Intuitive Surgical Price Performance

ISRG traded up $8.56 on Friday, reaching $592.64. 2,630,118 shares of the company traded hands, compared to its average volume of 1,158,623. The company has a market cap of $211.09 billion, a price-to-earnings ratio of 95.28, a PEG ratio of 4.66 and a beta of 1.39. The stock's 50 day moving average price is $540.66 and its 200-day moving average price is $499.19. Intuitive Surgical, Inc. has a 52-week low of $362.14 and a 52-week high of $597.68.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last posted its quarterly earnings results on Thursday, October 17th. The medical equipment provider reported $1.56 EPS for the quarter, beating the consensus estimate of $1.24 by $0.32. Intuitive Surgical had a net margin of 28.51% and a return on equity of 13.41%. The business had revenue of $2.04 billion for the quarter, compared to analysts' expectations of $2.01 billion. As a group, equities research analysts forecast that Intuitive Surgical, Inc. will post 5.45 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on ISRG shares. BTIG Research upped their price target on shares of Intuitive Surgical from $535.00 to $561.00 and gave the company a "buy" rating in a report on Tuesday, November 26th. Piper Sandler reissued an "overweight" rating and set a $538.00 target price (up from $495.00) on shares of Intuitive Surgical in a research note on Friday, October 18th. Wells Fargo & Company lifted their price target on shares of Intuitive Surgical from $549.00 to $630.00 and gave the stock an "overweight" rating in a research report on Wednesday, December 11th. Oppenheimer reaffirmed a "market perform" rating on shares of Intuitive Surgical in a report on Friday, October 18th. Finally, Raymond James raised their price objective on Intuitive Surgical from $500.00 to $540.00 and gave the stock an "outperform" rating in a research note on Monday, October 14th. One research analyst has rated the stock with a sell rating, four have given a hold rating and fifteen have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $554.17.

Insider Activity at Intuitive Surgical

In other Intuitive Surgical news, insider Jamie Samath sold 22,903 shares of Intuitive Surgical stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $525.00, for a total value of $12,024,075.00. Following the completion of the sale, the insider now directly owns 8,757 shares in the company, valued at $4,597,425. The trade was a 72.34 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Robert Desantis sold 376 shares of the business's stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $539.00, for a total transaction of $202,664.00. Following the completion of the sale, the executive vice president now directly owns 5,506 shares of the company's stock, valued at $2,967,734. This represents a 6.39 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 48,190 shares of company stock valued at $25,012,927. Insiders own 0.80% of the company's stock.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.